Qyuns Therapeutics Co., Ltd. Class H · HKEX:2509
Qyuns Therapeutics Co., Ltd. Class H — H1 2026 Earnings Presentation
32 slides from Qyuns Therapeutics Co., Ltd. Class H's earnings presentation, August 2026
Slide 1: Interim Results 2026
INTERIM RESULTS 2026 August 2026 2509.HK 0
Slide 2: Disclaimer
Disclaimer NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION OR DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAWS By attending this presentation or by reading this document, you (1) agree to be bound by the
Slide 3: Overview
01 2026 H1 at A Glance: Solid Execution Drives Tangible Results 02 Strong Delivery of Global Programs with Rapid BsAbs Advance Overview 03 Core MAbs Enter Harvest Phase with Strong Commercial Certainty 04 Robust Revenue Growth with Strengthened Financial Position
Slide 4: Qyuns: Leveraging Strong Comprehensive Capabilities to Capture Growth in China's Autoimmune Sector
Qyuns: Leveraging Strong Comprehensive Capabilities to Precisely Capture Growth Trends in China's Autoimmune Sector A biotech company exclusively focused on biologic therapies for autoimmune and allergic diseases Exclusive Focus Full Coverage Huge Market Potential Comprehensive Pipeline Focus on aut
Slide 5: Exclusive Focus on Autoimmune and Allergic Disease Therapies, Covering Four Major Disease Areas
Exclusive Focus on Autoimmune and Allergic Disease Therapies, Covering Four Major Disease Areas and Key Therapeutic Pathways mAbs bring commercial certainty; bsAbs boost efficacy and patient compliance IL-12/IL-23p40 Psoriasis IL-23p19 Psoriasis Ankylosing Spondylitis IL-17A Atopic Dermatitis IL-4Rα
Slide 6: Seasoned Management Team with Extensive Industry Experience
Seasoned Management Team with Extensive Industry Experience and Successful Entrepreneurial Track Records Jiwan Qiu Yiliang Wu Executive Director, Chairman, General Manager Executive Director, General Manager of Cellularforce 30 years of extensive R&D experience in biotechnology industry Weidong Lin
Slide 7: Cellularforce: Commercial Scale Production Capacity Supporting Rapid CDMO Growth
Cellularforce: Commercial Scale Production Capacity Supporting Rapid CDMO Growth Commercial-scale in-house manufacturing capability with China GMP cGMP-standard manufacturing facility with excellent CMC capability certification and EU QP audit clearance and quality management will secure high qualit
Slide 8: An Integrated Strategic Alliance Spanning R&D, Production and Commercialization
An Integrated Strategic Alliance: Forged by Forward-Looking Layout and Seamless Integration of the Full Industry Chain, Spanning R&D, Production and Commercialization Early Research Pre-clinical Study Clinical Development Production Partners Innovative structural platform for rabbit 9 self-developed
Slide 9: Strategic Cooperation: Verify Pipeline Value, Generate Cash Income
Strategic Cooperation: Verify Pipeline Value, Generate Cash Income, Accelerate Clinical Progress, Enhance Commercial Certainty 8
Slide 10: 2026 H1 at A Glance: Solid Execution Drives Tangible Results
2026 H1 at A Glance: 01 Solid Execution Drives Tangible Results 9
Slide 11: A Stellar Global Launch, Rapid BsAb Advance, MAbs Reaching Harvest Phase
A Stellar Global Launch, Rapid BsAb Advance, MAbs Reaching Harvest Phase Global programs SAILEXIN on track with is maintaining key milestones a rapid delivered growth momentum • QX031N initiated Phase I enrollment and triggered a milestone payment from Roche； • Windward closed an upsized USD 165 mil
Slide 12: Revenue Surged Over 100% YOY, Strengthening Future Capital Reserve
Revenue Surged Over 100% YOY, Strengthening Future Capital Reserve Revenue in H1 Adjusted Net Profit for H1* Mid-Year Cash Balance RMB 424 million RMB 202 million RMB 1.018 Billion * Adjusted Net Profit for H1 does not include the amortization of share-based compensation 11
Slide 13: MAbs and BsAbs Portfolios Form the Foundation for a Comprehensive Pipeline
MAbs and BsAbs Portfolios Form the Foundation for a Comprehensive and Synergistic Pipeline IND NDA Drug Target Indication Preclinical Phase I Phase II Phase III Partners Approval Approval QX001S Ps IL-12/ SAILEXIN IL-23p40 SAIJIENING CD PN QX005N IL-4Rα AD Oturkibart CRSwNP QX002N IL-17A AS Crusekit
Slide 14: Strong Delivery of Global Programs with Rapid BsAbs Advance
Strong Delivery of Global Programs 02 with Rapid BsAbs Advance 13
Slide 15: QX027N / WIN027 (TSLP/IL-13) - Long-acting BsAb
QX027N / WIN027 (TSLP/IL-13) - Long-acting BsAb for Dermatological and Respiratory Diseases Partner： $ 700 million partnership with Windward Bio Clinical-stage biotechnology company with deep discovery, development, and commercialization expertise committed to transforming the treatment of people li
Slide 16: QX030N / CLD-423 (IL-23p19/TL1A) - Long-acting BsAb for IBD
QX030N / CLD-423 (IL-23p19/TL1A) - Long-acting BsAb for IBD Partner： $ 555 million partnership with Caldera Latest Development：The first subject for the phase I trial in Australia was enrolled in January 2026, and the subject completed dosing. ⚫ Potential next generation IBD Management Team Backgrou
Slide 17: QX031N / RG6981 (TSLP/IL-33) - Long-acting BsAb for COPD and Asthma
QX031N / RG6981 (TSLP/IL-33) - Long-acting BsAb for COPD and Asthma $ 1.07 billion partnership with Roche Latest Development: Phase I first subject was dosed in New Zealand in ⚫ Potential to be a “First-in-class” March 2026, triggering a milestone payment. and “Best-in-disease” therapy Product Brief
Slide 18: QX035N – Next-Generation Long-acting c-kit BsAb
QX035N – Next-Generation Long-acting c-kit BsAb for Dermatological and Respiratory Diseases Next-generation allergy pipeline QX035N is an investigational long-acting bsAb that targets c-kit (a type III receptor tyrosine kinase) and an undisclosed second target. It is specifically designed to inhibit
Slide 19: Core MAbs Enter Harvest Phase with Strong Commercial Certainty
Core MAbs Enter Harvest Phase with Strong 03 Commercial Certainty 18
Slide 20: SAILEXIN/SAIJIENING – 1st Ustekinumab Biosimilar Approved in China
SAILEXIN/SAIJIENING – 1st Ustekinumab Biosimilar Approved in China & Blockbuster Thesis Playing Out Market Opportunities and Competition Competitive Advantages Market Opportunities Ustekinumab Global Sales The first marketed Ustekinumab Biosimilar in China (SAILEXIN/SAIJIENING) ✓ 2026 H1 sales excee
Slide 21: Crusekitug (QX002N) – IL-17A mAb for AS, with Clear Imaging Evidence
Crusekitug (QX002N) – IL-17A mAb for AS, with Clear Imaging Evidence Market Opportunities and Competition Competitive Advantages Market Opportunities IL-17A vs. TNF ✓ Guided as 2L standalone treatment for AS, IL-17A inhibitors have shown The AS patient population in China reached 3.9 million in 2022
Slide 22: Oturkibart (QX005N / HDM3016) – IL-4Rα mAb with Differentiated Positioning
Oturkibart (QX005N / HDM3016) – IL-4Rα mAb with Differentiated Positioning Mechanism Strategic Cooperation • IL-4Rα controls the signaling of both IL-4 and IL-13, which is critical in the initiation of type 2 inflammation • QX005N is designed to inhibit IL-4Rα, a well-validated, ⚫ In July 2024, the
Slide 23: Oturkibart (QX005N) – Leading Progress in PN Development
Oturkibart (QX005N) – Leading Progress in PN Development Market Opportunities and Competition Unmet Medical Needs • Development of the PN drug market in China is still at an Limitation of Prevalence of PN in China, 2017-2030E early stage current Thousand treatment • Current treatment (topical steroi
Slide 24: Oturkibart (QX005N) – Treatment for Moderate-to-Severe AD
Oturkibart (QX005N) – Treatment for Moderate-to-Severe AD, Covering Both Adolescent and Adult Patients Market Opportunities and Competition Unmet Medical Needs Market Opportunities • Systemic immunosuppressants face significant safety concerns AD patients in China reached 70.3 million in 2022 and ar
Slide 25: QX004N / HS-20137 – IL-23p19 mAb for Ps and CD
QX004N / HS-20137 – IL-23p19 mAb for Ps and CD, Top 2 Most Advanced Domestically IL-23p19 is currently a better target for psoriasis, Skyrizi® Global Sales the treatment effect of psoriasis will be further USD Million 17,562 improved, and it is conducive to long-term management. 11,718 9,988 7,760 5
Slide 26: QX008N / JKN2401 – TSLP mAb for Respiratory Diseases
QX008N / JKN2401 – TSLP mAb for Respiratory Diseases, Fastest COPD Progress in China Tezspire® Global Sales •TSLP is a cytokine expressed by the airway epithelium and sits at the top of multiple inflammatory cascades USD Million •Anti-TSLP mAb is the only biologic drug that is independent of 1,936 e
Slide 27: Robust Revenue Growth with Strengthened Financial Position
Robust Revenue Growth 04 with Strengthened Financial Position 26
Slide 28: Over 100% Operating Revenue Growth YOY; Profit-Sharing Realized
Over 100% Operating Revenue Growth YOY; Profit-Sharing for SAILEXIN/SAIJIENING Realized In the first half of 2026, Qyuns recorded a total revenue of RMB 424.1 million, representing a 105.37% increase RMB Million period-to-period. 600 In the first half of 2026, the Company's revenue was mainly derive
Slide 29: Net Profit Reached Nearly RMB 200 Million
Net Profit Reached Nearly RMB 200 Million, Represented a Significant Period-to-Period Increase In the first half of 2026, Qyuns recorded a net profit of RMB Million RMB 198.6 million, a significant turnaround from a net loss of RMB 30.9 million in the first half of 2025, representing an 400 increase
Slide 30: Ample Cash Reserves and Sufficient Credit Facilities
Ample Cash Reserves and Sufficient Credit Facilities Sufficient Cash Reserves: As of June 30, 2026, Cash and cash equivalents, Cash Reserves* restricted cash, time deposits, and financial assets at fair value through profit or RMB Million loss amounted to RMB 1,017.74 million, indicating ample cash
Slide 31: Healthy Debt Ratios with Strong Debt-Servicing Capacity
Healthy Debt Ratios with Strong Debt-Servicing Capacity Debt-to-Asset ratio 2026.6.30 – 2025.12.31 The debt-to-asset ratio of Qyuns declined from 57.6% as of December 31, 2025, to 56.0% as of June 30, 100 2026. The current ratio slightly increased from 2.2 as of December 31, 2025, to 2.3 as of June
Slide 32: IR@qyuns.net
IR@qyuns.net 31